Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer

September 19, 2016 10:40 AM EDT
Get Alerts SRPT Hot Sheet
Price: $32.86 +0.61%

Rating Summary:
    16 Buy, 9 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 27 | Down: 20 | New: 14
Trade SRPT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA announced the approval of eteplirsen (EXONDYS51) for the treatment of DMD amenable to Exon 51 skipping.

In conjunction with eteplirsen's accelerated approval, Sarepta will receive a pediatric review voucher that could be worth up to $350M.

"Notably, the label includes all patients with DMD amenable to exon 51 skipping, and does not restrict use by ambulatory status nor age," the analyst notes.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Add Your Comment